Total Payments
$17,528
2024 Payments
$59.68
Companies
9
Transactions
39
Medicare Patients
500
Medicare Billing
$55,638
Payment Breakdown by Category
Consulting$9,378 (53.5%)
Research$6,459 (36.8%)
Travel$938.42 (5.4%)
Food & Beverage$715.07 (4.1%)
Education$37.65 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,378 | 4 | 53.5% |
| Unspecified | $6,459 | 17 | 36.8% |
| Travel and Lodging | $938.42 | 3 | 5.4% |
| Food and Beverage | $715.07 | 14 | 4.1% |
| Education | $37.65 | 1 | 0.2% |
Payments by Type
General
$11,069
22 transactions
Research
$6,459
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $6,459 | 17 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $5,743 | 10 | $0 (2019) |
| GlaxoSmithKline, LLC. | $4,062 | 2 | $0 (2020) |
| OptiNose US, Inc. | $812.11 | 2 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $230.91 | 2 | $0 (2018) |
| Kaleo, Inc. | $95.65 | 1 | $0 (2017) |
| GENZYME CORPORATION | $59.68 | 3 | $0 (2024) |
| Shire North American Group Inc | $37.65 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $27.71 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59.68 | 3 | GENZYME CORPORATION ($59.68) |
| 2023 | $27.71 | 1 | Regeneron Healthcare Solutions, Inc. ($27.71) |
| 2020 | $4,700 | 2 | GlaxoSmithKline, LLC. ($3,900) |
| 2019 | $6,144 | 12 | AstraZeneca Pharmaceuticals LP ($5,743) |
| 2018 | $2,680 | 8 | SANOFI-AVENTIS U.S. LLC ($2,549) |
| 2017 | $3,917 | 13 | SANOFI-AVENTIS U.S. LLC ($3,509) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Immunology | ||||||
| 02/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Immunology | ||||||
| 01/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Immunology | ||||||
| 11/09/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.71 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/04/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 05/07/2020 | OptiNose US, Inc. | Xhance (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/25/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: Respiratory | ||||||
| 11/25/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $778.00 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Travel and Lodging | In-kind items and services | $453.10 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Travel and Lodging | In-kind items and services | $406.12 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Travel and Lodging | In-kind items and services | $79.20 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $50.01 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Respiratory | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $8.04 | General |
| Category: Respiratory | ||||||
| 06/30/2019 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $263.59 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
| 03/30/2019 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $137.13 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
| 12/31/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $897.60 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
| 12/31/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $535.16 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
| 11/17/2018 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $12.11 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 09/30/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $238.43 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
| 09/30/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $211.93 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
| 06/30/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $377.08 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
| 03/31/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $288.72 | Research |
| Study: A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis • Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis | SANOFI-AVENTIS U.S. LLC | $4,285 | 12 |
| NPPOC | SANOFI-AVENTIS U.S. LLC | $1,500 | 4 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | SANOFI-AVENTIS U.S. LLC | $673.94 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 234 | 328 | $134,915 | $30,058 |
| 2020 | 7 | 266 | 334 | $126,442 | $25,580 |
Total Patients
500
Total Services
662
Medicare Billing
$55,638
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 86 | 125 | $58,675 | $13,339 | 22.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 44 | 69 | $32,627 | $7,436 | 22.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 70 | 89 | $29,535 | $6,535 | 22.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $12,539 | $2,452 | 19.6% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 16 | 27 | $1,539 | $296.46 | 19.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 98 | 146 | $65,386 | $13,232 | 20.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 62 | 67 | $20,655 | $4,198 | 20.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 34 | 37 | $16,574 | $3,427 | 20.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $10,076 | $1,926 | 19.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 21 | 21 | $6,455 | $1,280 | 19.8% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 12 | 12 | $5,352 | $1,162 | 21.7% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2020 | 24 | 36 | $1,944 | $357.07 | 18.4% |
About Dr. Daniel Hamilos, M.D
Dr. Daniel Hamilos, M.D is a Allergy & Immunology healthcare provider based in Mason City, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558347047.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Hamilos, M.D has received a total of $17,528 in payments from pharmaceutical and medical device companies, with $59.68 received in 2024. These payments were reported across 39 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($9,378).
As a Medicare-enrolled provider, Hamilos has provided services to 500 Medicare beneficiaries, totaling 662 services with total Medicare billing of $55,638. Data is available for 2 years (2020–2021), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Clinical & Laboratory Immunology, Internal Medicine
- Location Mason City, IA
- Active Since 12/16/2005
- Last Updated 10/23/2023
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1558347047
Products in Payments
- DUPIXENT (Drug) $6,459
- FASENRA (Drug) $5,743
- NUCALA (Biological) $4,062
- Xhance (Drug) $812.11
- XOLAIR (Biological) $230.91
- Auvi-Q (Drug) $95.65
- DUPIXENT (Biological) $87.39
- CUVITRU (Biological) $37.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.